WO2005058358B1 - Use of agents derived from ceacam1 for the treatment of inflammatory diseases - Google Patents
Use of agents derived from ceacam1 for the treatment of inflammatory diseasesInfo
- Publication number
- WO2005058358B1 WO2005058358B1 PCT/EP2004/014435 EP2004014435W WO2005058358B1 WO 2005058358 B1 WO2005058358 B1 WO 2005058358B1 EP 2004014435 W EP2004014435 W EP 2004014435W WO 2005058358 B1 WO2005058358 B1 WO 2005058358B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fragment
- immunoglobulin
- biliary glycoprotein
- fusion protein
- ceacaml
- Prior art date
Links
- 200000000018 inflammatory disease Diseases 0.000 title claims abstract 5
- 102000003886 Glycoproteins Human genes 0.000 claims abstract 11
- 108090000288 Glycoproteins Proteins 0.000 claims abstract 11
- 102000018358 Immunoglobulins Human genes 0.000 claims abstract 11
- 108060003951 Immunoglobulins Proteins 0.000 claims abstract 11
- 241000124008 Mammalia Species 0.000 claims abstract 6
- 102000037240 fusion proteins Human genes 0.000 claims abstract 6
- 108020001507 fusion proteins Proteins 0.000 claims abstract 6
- 229920001184 polypeptide Polymers 0.000 claims abstract 5
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims abstract 4
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 238000004132 cross linking Methods 0.000 claims abstract 2
- 230000000051 modifying Effects 0.000 claims abstract 2
- 230000001225 therapeutic Effects 0.000 claims abstract 2
- 230000027455 binding Effects 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 229920000023 polynucleotide Polymers 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 206010003246 Arthritis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Abstract
The use of an agent that selectively modulates cross-linking of biliary glycoprotein polypeptides for the preparation of a pharmaceutical composition for preventing or treatment of a mammal subject afflicted with an inflammatory disease is provided. In particular, a method for preventing or treatment of a mammal subject afflicted with rheumatoid arthritis or multiple sclerosis, comprising the step of administering to a mammal in need thereof a therapeutic effective amount of a fusion protein of a fragment of biliary glycoprotein and a fragment of an immunoglobulin is described.
Claims
1. Use of an agent that selectively modulates cross-linking of biliary glycoprotein polypeptides for the preparation of a pharmaceutical composition for preventing or treatment of a mammal subject afflicted with an inflammatory disease.
2. The use of claim 1, wherein said inflammatory disease is arthritis or multiple sclerosis (MS).
3. The use of claim 2, wherein said inflammatory disease is rheumatoid arthritis (RA).
4. The use of any one of claims 1 to 3, wherein the agent is an antibody.
5. The use of claim 4, wherein the antibody is a monoclonal antibody.
6. The use of any one of claims 1 to 3, wherein the agent comprises a ligand for the biliary glycoprotein polypeptide, wherein the ligand binds at least one biliary glycoprotein polypeptides.
7. The use of claim 6, wherein the ligand is fused to an immunoglobulin molecule or a fragment thereof.
8. The use of claim 6 or 7, wherein the ligand comprises a biliary glycoprotein polypeptide or fragment thereof.
9. The use of any one of claims 6 to 8, wherein said biliary glycoprotein is a human biliary glycoprotein (CEACAMl) or a fragment thereof.
10. The use of claim 9, wherein said fragment is derived from the extracellular domain of CEACAMl.
11. The use of any one of claims 7 to 10, wherein said immunoglobulin is a human immunoglobulin or a fragment thereof.
12. The use of claim 11, wherein said immunoglobulin fragment of the immunoglobulin is the Fc portion of the immunoglobulin.
13. The use of any one of claims 9 to 12, wherein said biliary glycoprotein fragment comprises the amino sequence from position 1 to 228 of SEQ ID NO: 2 (Figure 1) or a fragment thereof and/or the immunoglobulin fragment comprises the hinge-CH2-CH3 region of the Fc portion of the immunoglobulin.
14. The use of any one of claims 1 to 13, wherein the dosage is in the range of 0.1 mg/kg/day to 25 mg/kg/day.
15. The use of any one of claims 1 to 14, wherein the pharmaceutical composition is adapted in a form to be administered intravenously, subcutaneous, intramuscular or by inhalation.
16. A fusion protein comprising a human biliary glycoprotein (CEACAMl) fragment which is derived from the extracellular domain of CEACAMl and an Fc portion of a human immunoglobulin.
17. The fusion protein of claim 16, wherein said CEACAMl fragment substantially consists of the amino sequence from position 1 to 228 of SEQ ID NO: 2 (Figure 1) or a fragment thereof.
18. A polynucleotide encoding the fusion protein of claim 16 or 17.
19. A vector comprising the polynucleotide of claim 18.
20. A host cell comprising a polynucleotide of claim 18 or a vector of claim 19.
21. A composition comprising the fusion protein of claim 16 or 17, the polynucleotide of claim 18, the vector of claim 19 or the cell of claim 20, optionally in combination with a pharmaceutically acceptable carrier. 27
22. A method for preventing or treatment of a mammal subject afflicted with rheumatoid arthritis or multiple sclerosis, comprising the step of administering to a mammal in need thereof a therapeutic effective amount of a fusion protein of a fragment of biliary glycoprotein and a fragment of an immunoglobulin.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04804036A EP1701739A2 (en) | 2003-12-17 | 2004-12-17 | Use of agents derived from ceacam1 for the treatment of inflammatory diseases |
| US10/583,291 US20080026980A1 (en) | 2003-12-17 | 2004-12-17 | Use of Agents Derived from Ceacam1 for the Treatment of Inflammatory Diseases |
| US12/806,002 US20110189181A1 (en) | 2003-12-17 | 2010-08-02 | Use of agents derived from CEACAM1 for the treatment of inflammatory diseases |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03028968.0 | 2003-12-17 | ||
| EP03028968 | 2003-12-17 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/806,002 Continuation US20110189181A1 (en) | 2003-12-17 | 2010-08-02 | Use of agents derived from CEACAM1 for the treatment of inflammatory diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2005058358A2 WO2005058358A2 (en) | 2005-06-30 |
| WO2005058358A3 WO2005058358A3 (en) | 2005-11-24 |
| WO2005058358B1 true WO2005058358B1 (en) | 2006-01-26 |
Family
ID=34684544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2004/014435 WO2005058358A2 (en) | 2003-12-17 | 2004-12-17 | Use of agents derived from ceacam1 for the treatment of inflammatory diseases |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US20080026980A1 (en) |
| EP (1) | EP1701739A2 (en) |
| WO (1) | WO2005058358A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003054019A2 (en) | 2001-12-21 | 2003-07-03 | Genpat77 Pharmacogenetics Ag | Therapeutic monoclonal anti-tirc7 antibodies for use in immune related and other diseases |
| KR101050298B1 (en) * | 2008-12-03 | 2011-07-19 | 삼성에스디아이 주식회사 | Secondary battery |
| US9556271B2 (en) | 2011-12-01 | 2017-01-31 | The Brigham And Women's Hospital, Inc. | Anti-CEACAM1 recombinant antibodies for cancer therapy |
| CA2916638C (en) | 2012-07-31 | 2021-01-12 | The Brigham And Women's Hospital, Inc. | Modulation of the immune response |
| WO2016120331A1 (en) | 2015-01-28 | 2016-08-04 | Karl Sebastian Lang | Agonistic anti-cd66cd66 antibody for antiviral therapy |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2328725A1 (en) * | 1998-04-15 | 1999-10-21 | Brigham & Women's Hospital, Inc. | T cell inhibitory receptor compositions and uses thereof |
-
2004
- 2004-12-17 WO PCT/EP2004/014435 patent/WO2005058358A2/en active Application Filing
- 2004-12-17 US US10/583,291 patent/US20080026980A1/en not_active Abandoned
- 2004-12-17 EP EP04804036A patent/EP1701739A2/en not_active Withdrawn
-
2010
- 2010-08-02 US US12/806,002 patent/US20110189181A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9328157B2 (en) | Inhibitors of type 2 vascular endothelial growth factor receptors | |
| JP6618854B2 (en) | Engineered polypeptides with increased duration of action and reduced immunogenicity | |
| CA2412494A1 (en) | Agonist anti-trk-c monoclonal antibodies | |
| US20170096497A1 (en) | Use of antibody conjugates | |
| JP2018515088A5 (en) | ||
| CA2501984A1 (en) | Erythropoietin receptor binding antibodies | |
| JP2008500373A5 (en) | ||
| CA2386463A1 (en) | April receptor (bcma) and uses thereof | |
| CA2253239C (en) | Antibodies against interferon alpha/beta receptor | |
| JP2016512213A5 (en) | ||
| CA3173919A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer | |
| CA2356737A1 (en) | Tumor necrosis factor antagonists and their use in endometriosis | |
| US20070042963A1 (en) | Therapeutic peptides | |
| WO2005058358B1 (en) | Use of agents derived from ceacam1 for the treatment of inflammatory diseases | |
| IL310164A (en) | Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases | |
| JPWO2019121906A5 (en) | FC binding fragment with PD-LI antigen binding site | |
| WO2019204402A1 (en) | Compositions and methods for treatment of cancer | |
| US20230391892A1 (en) | Bifunctional antagonists of tumor necrosis factor alpha and transforming growth factor beta and uses thereof | |
| WO2024046301A1 (en) | Fusion protein comprising taci polypeptide and use thereof | |
| US20230391880A1 (en) | Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof | |
| CN108601819B (en) | Amelioration of systemic sclerosis with death receptor agonists | |
| CA3232777A1 (en) | Novel interferon variants and bifunctional fusion molecules thereof | |
| CA3196112A1 (en) | Bifunctional antagonists of activin and tumor necrosis factor-alpha and uses thereof | |
| JP2006528663A5 (en) | ||
| CA3197104A1 (en) | Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof |